Fluicell

Fluicell Days Payable Outstanding

The Days Payable Outstanding (DPO) of Fluicell (FLUI.ST) as of Nov 19, 2026 is 32.38. In the previous year, Days Payable Outstanding (DPO) was 206.04 — a change of -84.28% (lower).

Days Payable Outstanding

32.38

YoY

-84.28%

Last updated:

Days Payable Outstanding (DPO) of Fluicell is 2025 32.38 . Days Payable Outstanding (DPO) of Fluicell was 2024 206.04 . It decreases by -84.28% lower compared to the previous year.

The Fluicell Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2018
797.21 SEK
Jan 1, 2019
1,538.27 SEK
Jan 1, 2020
271.90 SEK
Jan 1, 2021
534.48 SEK
Jan 1, 2022
472.35 SEK
Jan 1, 2023
343.10 SEK
Jan 1, 2024
206.04 SEK
Jan 1, 2025
32.38 SEK
The Fluicell Days Payable Outstanding history
YEARDays Payable OutstandingYoY
32.38-84.28%
206.04-39.95%
343.10-27.36%
472.35-11.62%
534.48+96.57%
271.90-82.32%
1,538.27+92.96%
797.21+2,344.28%
32.62+200.22%
10.86+170.18%
4.02-99.63%
1,080.72—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

Days Payable Outstanding (DPO) of Fluicell is 32.38 in 2025.

Days Payable Outstanding (DPO) of Fluicell changed from 206.04 to 32.38, representing a -84.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Fluicell since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Fluicell with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Fluicell

All Key Metrics — Fluicell